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ETTERS TO THE EDITOR
eclassifying inﬂammatory bowel disease

ment  for  performing  a  cost-effective  test  in  the  pediatric
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7ith  capsule endoscopy in children
 reclassiﬁcac¸ão de doenc¸a inﬂamatória
ntestinal  com cápsula endoscópica em
rianc¸as
e  read  with  great  interest  the  article  by  Ouahed  et  al.1
n  the  role  of  wireless  capsule  endoscopy  in  reclassify-
ng inﬂammatory  bowel  disease  in  children.  It  was  the
rst prospective  study  concerning  reclassiﬁcation  of  inﬂam-
atory bowel  disease  unclassiﬁed  (IBDU)  in  the  pediatric
opulation. It  is  an  addition  to  the  growing  evidence  of
he role  of  capsule  endoscopy  (CE)  in  this  subtype  of
nﬂammatory bowel  disease,  both  in  pediatric  and  adult
opulations.1--6
There  is  currently  no  validated  scoring  system  for  the
iagnosis of  small  bowel  Crohn’s  disease  (SBCD).  Most  studies
se the  consensus  criterion  of  three  or  more  ulcers  as  pre-
ictive of  SBCD  in  adults.7 There  is  no  evidence  whether  this
riterion can  safely  predict  SBCD  in  the  pediatric  population,
earing in  mind  that  mucosal  breaks  can  occur  in  healthy
dults,8 and  the  type  and  severity  of  mucosal  changes  in
ealthy children  is  yet  to  be  determined.  In  addition,  and  as
entioned by  the  authors,  non-steroidal  anti-inﬂammatory
rugs (NSAIDs)  can  mimic  SBCD  at  capsule  endoscopy;  there-
ore, this  data  should  have  been  provided  by  the  authors.
his does  have  a  bearing  on  the  sensitivity  and  speciﬁcity  of
hat study.
Studies within  adult  populations  have  shown  a  dis-
arity in  the  management  of  post-CE  outcomes  among
ymptomatic2,5,6 versus  asymptomatic3 IBDU  patients.
herefore, it  would  be  worth  knowing  whether  the  patients
ere symptomatic  at  the  time  of  CE.  In  addition,  although
he authors  mention  a  change  in  the  management  of  three
atients, it  would  be  useful  to  know  the  details  of  the  post-
E change  in  medical  therapy  to  truly  assess  the  impact  of
 positive  or  negative  CE.  It  would  also  strengthen  the  argu-
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021-7557  © 2013 Sociedade Brasileira de Pediatria. Published by ElseviWe agree  with  the  authors  that  CE  is  a  novel  tool  in  re-
lassifying IBDU  patients,  compared  to  standard  small  bowel
nvestigations. It  must  be  said  however,  that  CE  ﬁndings
ith no  histological  conﬁrmation  would  need  to  be  inter-
reted with  caution  and  with  regard  to  clinical  context,  as
 false  positive  could  result  in  intensiﬁed  therapy  and  cause
sychological side  effects.9
eferences
. Ouahed J, Shagrani M, Sant’Anna A. Role of wireless capsule
endoscopy in reclassifying inﬂammatory bowel disease in chil-
dren.  J Pediatr (Rio J). 2013;89:204--9.
. Kalla R, McAlindon ME, Drew K, Sidhu R. Clinical utility of
capsule endoscopy in patients with Crohn’s disease and inﬂam-
matory bowel disease unclassiﬁed. Eur J Gastroenterol Hepatol.
2013;25:706--13.
.  Lopes S, Figueiredo P, Portela F, Freire P, Almeida N, Lérias
C, et al. Capsule endoscopy in inﬂammatory bowel disease
type unclassiﬁed and indeterminate colitis serologically nega-
tive.  Inﬂamm Bowel Dis. 2010;16:1663--8.
.  Mehdizadeh S, Chen G, Enayati PJ, Cheng DW, Han NJ, Shaye OA,
et  al. Diagnostic yield of capsule endoscopy in ulcerative coli-
tis  and inﬂammatory bowel disease of unclassiﬁed type (IBDU).
Endoscopy. 2008;40:30--5.
. Maunoury V, Savoye G, Bourreille A, Bouhnik Y, Jarry M,
Sacher-Huvelin S, et al. Value of wireless capsule endoscopy
in patients with indeterminate colitis (inﬂammatory bowel
disease type unclassiﬁed). Inﬂamm Bowel Dis. 2007;13:
152--5.
.  Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu-Martin
MT, et al. Initial experience with wireless capsule enteroscopy in
the  diagnosis and management of inﬂammatory bowel disease.
Clin Gastroenterol Hepatol. 2004;2:31--40.
.  Bourreille A, Ignjatovic A, Aabakken L, Loftus Jr EV, Eli-
akim R, Pennazio M, et al. Role of small-bowel endoscopy
in the management of patients within ﬂammatory bowel
disease: an international OMED-ECCO consensus. Endoscopy.
2009;41:618--37.
.  Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S,
Fort JG, et al. Video capsule endoscopy to prospectively
assess small bowel injury with celecoxib, naproxen plus
omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:
133--41.
.  Gailhoustet L, Goulet O, Cachin N, Schmitz J. Study of psycholog-
ical repercussions of 2 modes of treatment of adolescents with
Crohn’s disease. Arch Pediatr. 2002;9:110--6.
er Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
LETTERS  TO  THE  EDITOR  515
Shruti  Shree  Joshia,  Arpita  Kalla  Vyasb,  Dinesh  Vyasc ,
Rahul  Kallad,∗
a MBBS,  Department  of  Medicine,  Maidstone  General
Hospital,  Maidstone,  Kent,  United  Kingdom
b MBcHB  MD,  Department  of  Pediatrics  and  Human
Development,  Michigan  State  University,  East  Lansing,
United  States
c MD  MS  FICS,  Department  of  Surgery,  Nanomedical
OncoSepsis  Lab,  Institute  of  International
Health,  College  of  Human  Medicine,  Michigan  State
University,  East  Lansing,  United  States
d MBcHB  MRCP,  Gastroenterology  &  Liver  Unit,  Manchester
Royal Inﬁrmary,  Oxford  Road,  Manchester,  United  Kingdom
∗Corresponding  author.
E-mail: kallarahul@gmail.com  (R.  Kalla).
http://dx.doi.org/10.1016/j.jped.2013.07.002
Reply to ‘‘Reclassifying inﬂammatory
bowel  disease with capsule endoscopy in
children’’
Resposta à ‘‘Reclassiﬁcac¸ão da doenc¸a
inﬂamatória  intestinal com cápsula
endoscópica  em crianc¸as’’
In  response  to  the  letter  to  the  editor  by  Joshi  et  al.,  we
agree that  the  scoring  system  for  the  diagnosis  of  small
bowel disease  with  capsule  endoscopy  (CE)  using  three  or
more ulcers  is  not  ideal,  as  it  doesn’t  include  tissue  sam-
ples, but  it  has  been  accepted  currently  as  a  consensus.1 It
was not  initially  reported  by  us,  but  none  of  the  children
were taking  non-steroidal  anti-inﬂammatory  drugs  (NSAIDs)
at the  time  of  the  study,  as  we  were  aware  of  the  possible
mucosal breaks  secondary  to  the  use  of  NSAIDS.2
As  stated  in  our  article,  all  patients  were  investigated  at
their initial  diagnosis  of  inﬂammatory  bowel  disease  (IBD).
It was  not  described  in  details;  however,  all  patients  were
symptomatic (iron  deﬁciency  anemia,  abdominal  pain,  diar-
rhea, blood  in  stools),  justifying  the  investigation  to  rule  out
IBD.  The  capsule  study  was  performed  within  three  months
of the  initial  investigations.
Regarding  the  management  of  patients  after  the  capsule
study, one  patient  was  started  on  azathioprine  early  in  the
course of  disease,  one  patient  was  started  on  budesonide,
and one  patient  (negative  study)  was  discontinued  from
mesalamine. It  is  important  to  reinforce  that  all  patients
were followed  in  the  IBD  clinic  at  the  McMaster  Children’s
Hospital for  12  months  after  the  capsule  study,  conﬁrming
as  there  is  not  yet  a  histological  conﬁrmation  available  with
the CE  study.
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